In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Iovance Biotherapeutics (IOVA – Research Report). The company’s shares closed yesterday at $6.07.

In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against other Billionaire Joseph Edelman’s long-term stock picks. Joseph Edelman is a ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report) today. The company’s shares closed yesterday at $5.78. Discover ...

In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against other Billionaire Joseph Edelman’s long-term stock picks. Joseph Edelman is a renowned ...

It was about a year ago that shares of Iovance Biotherapeutics (NASDAQ: IOVA) began to take off. The stock soared on news of approval from the Food and Drug Administration for Amtagvi (lifileucel ...

Iovance Biotherapeutics (NASDAQ: IOVA), a small-cap biotech company, has an innovative approach to treating cancer that relies on harnessing patients' cancer-fighting capabilities. Though the ...

Investors in Iovance Biotherapeutics Inc (Symbol: IOVA) saw new options begin trading this week, for the September 19th expiration. One of the key data points that goes into the price an option ...

IOVA Price Action: Iovance shares were down 8.28% at $6.58 at the time of writing, according to Benzinga Pro.

Shares of Iovance Biotherapeutics have been nosediving in recent months. Despite Amtagvi's approval, investors appear concerned with Iovance's financials. The biotech has been burning through cash ...